BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2016

Full document

Business Context and Reporting Period

This Form 8-K filing by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) covers events occurring on June 23, 2016. The report details the entry into a new material definitive agreement for an "at-the-market" equity offering and the termination of a prior sales agreement.

Key Financial Metrics and Agreements

  • New Offering Capacity: The Company entered into a Sales Agreement with FBR Capital Markets & Co. to sell up to $4,000,000 of common stock.
  • Compensation: FBR will receive a commission of 3.0% of gross proceeds plus up to $35,000 in expense reimbursement.
  • Prior Offering History: Under the terminated agreement with Cantor Fitzgerald & Co., the Company sold 1,368,933 shares from an authorized aggregate offering price of up to $8.35 million.
  • Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics.

Material Changes Versus Prior Period

The primary material change is the replacement of the equity distribution agent. Effective June 17, 2016, the Company terminated its Controlled Equity Offering SM sales agreement with Cantor Fitzgerald & Co. Subsequently, on June 23, 2016, the Company executed a new At Market Issuance Sales Agreement with FBR Capital Markets & Co. to facilitate future share sales.

Guidance, Outlook, and Risks

  • Outlook: The Company is not obligated to sell any shares under the new agreement. No assurance is given regarding the price, amount, or timing of any future sales.
  • Risks: Actual results may differ from expectations due to market conditions and pre-sale conditions. The filing includes standard forward-looking statement disclaimers under the Private Securities Litigation Reform Act of 1995.
  • Unusual Items: None reported in this filing.

Investor Verification Checklist

  • Verify the current market price of Cyclacel Pharmaceuticals, Inc. common stock to assess the potential dilution impact of the $4,000,000 offering.
  • Review the effective "shelf" registration statement (Form S-3, File No. 333-211046) for full terms of the offering.
  • Confirm the Company's current cash position and burn rate to understand the urgency of raising capital under the new agreement.
  • Check subsequent filings to determine if and when shares were actually sold under the FBR agreement.